Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Moderna has tapped Lonza to scale up the manufacturing of its experimental COVID-19 vaccine in a 10-year strategic collaboration that could ultimately produce…
The U.S. Food and Drug Administration today issued an Emergency Use Authorization for the second vaccine for the prevention of coronavirus disease…
As of the end of the public health emergency declaration on May 11, 2023, the Centers for Disease Control and Prevention reported approximately 104 million…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Moderna signed a 10-year strategic manufacturing agreement with Lonza for mRNA-1273 (Spikevax) and other mRNA medicines. Lonza established production lines in Portsmouth, NH (US) and Visp, Switzerland targeting four manufacturing kits each capable of producing up to 100M doses/year of mRNA-1273. Critical to global COVID-19 vaccine supply chain.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Moderna, Inc. / Lonza Group AG (this deal) | 2020 | — | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2020 deals · Infectious Disease deals